Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegbelfermin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 06 Dec 2018 Results assessing pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver, published in the Obesity (Silver Spring, Md.).
- 14 Apr 2018 Results of a population pharmacokinetics and exposure-response analysis from NCT02097277, NCT02413372 and one more study, presented at The International Liver Congress 2018.
- 14 Apr 2018 Results of an integrated safety analysis from NCT02097277 and NCT02413372 studies, presented at The International Liver Congress 2018.